Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic miceReport as inadecuate




Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice - Download this document for free, or read online. Document in PDF available to download.

Cardiovascular Diabetology

, 14:81

First Online: 16 June 2015Received: 12 March 2015Accepted: 06 June 2015

Abstract

BackgroundFactor Xa inhibitor is used for preventing venous thromboembolism VTE in adult patients receiving orthopedic operation. However, the role of factor Xa inhibitor, rivaroxaban, in angiogenesis is still unknown.

Methods and resultsStreptozotocin STZ–induced diabetic mice with model of hind-limb ischemia, were divided into non-diabetic control, diabetic control, and low- and high-dose rivaroxaban treatment groups, in order to evaluate the effect of rivaroxaban in angiogenesis. Doppler perfusion imaging showed that blood flow recovery was significantly increased, and more capillary density occurred in the rivaroxaban treatment group. In vitro studies, human endothelial progenitor cells EPCs treated with rivaroxaban had significant functional improvement in migration and senescence under hyperglycemic conditions. Rivaroxaban also increased endothelial nitric oxide synthase eNOS as well as vascular endothelial growth factor VEGF expressions in hyperglycemia-stimulated EPCs.

ConclusionsRivaroxaban promoted vessel formation in diabetic mice and improved endothelial progenitor cell function under hyperglycemic conditions. These effects may be associated with enhancement of expression of eNOS and VEGF.

KeywordsFactor Xa inhibitor Diabetes Angiogenesis Endothelial progenitor cells AbbreviationseNOSEndothelial nitric oxide synthase

EPCsEndothelial progenitor cells

FACSFluorescence-activated cell sorting

FITCFluorescein isothiocyanate

IACUCInstitutional Animal Care Committee

NONitric oxide

PEPhycoerythrin

ROSReactive oxidative stress

SEMStandard error of mean

STZStreptozotocin

VEGFVascular endothelial growth factor

VTEVenous thromboembolism

Download fulltext PDF



Author: Tao-Cheng Wu - Jenq-Shyong Chan - Chiu-Yang Lee - Hsin-Bang Leu - Po-Hsun Huang - Jia-Shiong Chen - Shing-Jong Lin - Jaw-We

Source: https://link.springer.com/article/10.1186/s12933-015-0243-y







Related documents